RxDoctor Payments Data

Mohammad Anindo

Hospitalist · Hattiesburg, MSNPI 1003299876

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $313 and has fallen 51.3% since, to $153 in 2025.

$1,359in general payments, 2019–2025

Across 56 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$249
  • Boehringer Ingelheim$218
  • AbbVie$166
  • AstraZeneca$133
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$132
  • Pfizer$104
  • plus $356 from 8 others

What the payments were for

  • Food & beverage$1,27494%
  • Education$856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,359 in reported general payments places this provider in the 75th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$95,947
Medicare patients
389
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$15,348
Pantoprazole Sodium79$2,795
Cefazolin Sodium19$1,054
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$236
Sodium Chloride0.9 % Sodium Chloride20$197
Levetiracetam17$191
Atorvastatin Calcium30$131
Isosorbide Mononitrate ErIsosorbide Mononitrate14$124
Amlodipine Besylate19$112
Furosemide29$102
Metoprolol Succinate12$99
ClopidogrelClopidogrel Bisulfate28$97
Carvedilol19$81
Levofloxacin28$79
Metoprolol Tartrate22$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$15,34823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →